<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094770</url>
  </required_header>
  <id_info>
    <org_study_id>0431-024</org_study_id>
    <secondary_id>MK0431-024</secondary_id>
    <secondary_id>2004_049</secondary_id>
    <nct_id>NCT00094770</nct_id>
  </id_info>
  <brief_title>An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this investigational study is to determine the safety and effectiveness of an
      investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of treatment is 104 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>HbA1c is measured as percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 104</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>HbA1c is measured as percent. Thus, this change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline at Week 52 is defined as Week 52 minus Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 104</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>Change from baseline at Week 104 is defined as Week 104 minus Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Events at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Number of participants who reported 1 or more episodes of the adverse experience (AEs) of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Events at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Number of participants who reported 1 or more episodes of the adverse experience of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Adverse Experiences (CAEs) at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious CAEs at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug-related CAEs at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious LAEs at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Serious LAEs are any LAEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug-related LAEs at Week 104</measure>
    <time_frame>Baseline to Week 104</time_frame>
    <description>Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1172</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg oral tablets of sitagliptin once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glipizide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin (MK0431)</intervention_name>
    <description>Sitagliptin 100 mg oral tablets of sitagliptin once daily.</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>MK0431</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: glipizide</intervention_name>
    <description>Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
    <arm_group_label>Glipizide</arm_group_label>
    <other_name>Glipizide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are at least 18 years of age and not older than 78 with type 2 diabetes
             mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 Mar;9(2):194-205.</citation>
    <PMID>17300595</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2004</study_first_submitted>
  <study_first_submitted_qc>October 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2004</study_first_posted>
  <results_first_submitted>September 24, 2009</results_first_submitted>
  <results_first_submitted_qc>November 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2009</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In: 26-Oct-2004; Last Patient Last Visit: 17-May-2007; 173 medical clinics worldwide.</recruitment_details>
      <pre_assignment_details>Participants 18-78 years of age with type 2 diabetes mellitus (T2DM) and inadequate glycemic control (Hemoglobin A1c &gt;6.5% and &lt; 10%) on metformin at a dose of &gt;1500mg/day.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
        </group>
        <group group_id="P2">
          <title>Glipizide</title>
          <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1 ( Week 0 to Week 52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="588"/>
                <participants group_id="P2" count="584"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="386">4 Participants who Completed Week 52, Did NOT Enter second year</participants>
                <participants group_id="P2" count="412">11 Participants who Completed Week 52, Did NOT Enter second year</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 2 (Week 0 to Week 104)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="588"/>
                <participants group_id="P2" count="584"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="320"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
        </group>
        <group group_id="B2">
          <title>Glipizide</title>
          <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="588"/>
            <count group_id="B2" value="584"/>
            <count group_id="B3" value="1172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="9.3"/>
                    <measurement group_id="B2" value="56.6" spread="9.8"/>
                    <measurement group_id="B3" value="56.7" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="0.9"/>
                    <measurement group_id="B2" value="7.6" spread="0.9"/>
                    <measurement group_id="B3" value="7.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 52</title>
        <description>HbA1c is measured as percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The per protocol population required that a participant had measurements both at baseline and at Week 52, and did not have any major protocol violations (e.g. drug compliance &lt; 75%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 52</title>
          <description>HbA1c is measured as percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent.</description>
          <population>The per protocol population required that a participant had measurements both at baseline and at Week 52, and did not have any major protocol violations (e.g. drug compliance &lt; 75%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" lower_limit="-0.75" upper_limit="-0.59"/>
                    <measurement group_id="O2" value="-0.67" lower_limit="-0.75" upper_limit="-0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Week 104</title>
        <description>HbA1c is measured as percent. Thus, this change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>The per protocol population required that a participant had measurements both at baseline and at Week 104, and did not have any major protocol violations (e.g. drug compliance &lt; 75%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 104</title>
          <description>HbA1c is measured as percent. Thus, this change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.</description>
          <population>The per protocol population required that a participant had measurements both at baseline and at Week 104, and did not have any major protocol violations (e.g. drug compliance &lt; 75%, addition of prohibited antihyperglycemic agent, incorrect double-blind study medication). No missing data were imputed.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" lower_limit="-0.64" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-0.60" upper_limit="-0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 52</title>
        <description>Change from baseline at Week 52 is defined as Week 52 minus Week 0.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The All-Patient-as-Treated (APaT) population required that a participant received at least 1 dose of double-blind study therapy. No missing data were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 52</title>
          <description>Change from baseline at Week 52 is defined as Week 52 minus Week 0.</description>
          <population>The All-Patient-as-Treated (APaT) population required that a participant received at least 1 dose of double-blind study therapy. No missing data were imputed.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-2.0" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.5" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 104</title>
        <description>Change from baseline at Week 104 is defined as Week 104 minus Week 0.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>The All-Patient-as-Treated (APaT) population required that a participant received at least 1 dose of double-blind study therapy. No missing data were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 104</title>
          <description>Change from baseline at Week 104 is defined as Week 104 minus Week 0.</description>
          <population>The All-Patient-as-Treated (APaT) population required that a participant received at least 1 dose of double-blind study therapy. No missing data were imputed.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.3" upper_limit="-1.0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Events at Week 52</title>
        <description>Number of participants who reported 1 or more episodes of the adverse experience (AEs) of hypoglycemia.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Events at Week 52</title>
          <description>Number of participants who reported 1 or more episodes of the adverse experience (AEs) of hypoglycemia.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with one or more Hypoglycemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of Hypoglycemic episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with no Hypoglycemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="559"/>
                    <measurement group_id="O2" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Events at Week 104</title>
        <description>Number of participants who reported 1 or more episodes of the adverse experience of hypoglycemia.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Events at Week 104</title>
          <description>Number of participants who reported 1 or more episodes of the adverse experience of hypoglycemia.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with one or more Hypoglycemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of Hypoglycemic episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with no Hypoglycemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557"/>
                    <measurement group_id="O2" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Adverse Experiences (CAEs) at Week 104</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Adverse Experiences (CAEs) at Week 104</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452"/>
                    <measurement group_id="O2" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious CAEs at Week 104</title>
        <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious CAEs at Week 104</title>
          <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524"/>
                    <measurement group_id="O2" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug-related CAEs at Week 104</title>
        <description>Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug-related CAEs at Week 104</title>
          <description>Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With drug related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without drug related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 104</title>
        <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 104</title>
          <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious LAEs at Week 104</title>
        <description>Serious LAEs are any LAEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious LAEs at Week 104</title>
          <description>Serious LAEs are any LAEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588"/>
                    <measurement group_id="O2" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug-related LAEs at Week 104</title>
        <description>Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Glipizide</title>
            <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug-related LAEs at Week 104</title>
          <description>Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs.</description>
          <population>All randomized participants who received at least 1 dose of the double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.</description>
        </group>
        <group group_id="E2">
          <title>Glipizide</title>
          <description>The Glipizide group includes data from patients randomized to receive treatment with glipizide initiated at a dose of 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRa Version 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Hearing Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Macular Hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal Strangulated Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rectal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Splenic Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Helicobacter Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Burns Third Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Postoperative Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tendon Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Muscle Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Astrocytoma Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Carcinoid Tumour Of The Small Bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant Non-Resectable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Metastases To Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oesophageal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma Of Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Loss Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Vaginal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pickwickian Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Venous Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRa Version 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="318" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="374" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="588"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

